PD-1/PD-L1-IN-43

Cat. No.:	HY-163534
Molecular Formula:	$C_{27}H_{25}N_3O_4$
Molecular Weight:	455.51
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between PD-1 and PD-L1. PD-1/PD-L1-IN-43 can be used in anti-tumor studies[1].

In Vitro

PD-1/PD-L1-IN-43 (0 - 20 μM; 48 h) can reactivate immunosuppressed Jurkat T cells to kill HepG2 cells in the cell co-culture system[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	HepG2/Jurkat co-culture cell model
Concentration:	0 - 20 μM
Incubation Time:	48 h
Result:	Reduced the survival rate of HepG2 cells to 55.16% compared to the control group.

In Vivo

PD-1/PD-L1-IN-43 (20 and 40 mg/kg; i.p.; everday for 2 weeks) inhibits potently tumor growth in vivo by activating the tumor immune microenvironment in C57BL/6J male mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mouse model of B16-F10 melanoma
Dosage:	20 and 40 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	The tumor growth inhibition values (TGI) of the treatment groups were 42.4 % and 52.6 % at doses of 20 and 40 mg/kg.

REFERENCES

[1]. Xu C, et al. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction[J]. Bioorganic Chemistry, 2024: 107376.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA